NECFA
BMRN icon

New England Capital Financial Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

New England Capital Financial Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-51
Closed -$5.65K – 439
2022
Q4 		$5.65K Buy
+51
New +$4.79K ﹤0.01% 288

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

New England Capital Financial Advisors's BMRN Position: Q1 2023 in Review

New England Capital Financial Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2023, closing a stake of 51 shares — an estimated $5.65K sold.

New England Capital Financial Advisors first reported a position in BMRN in Q4 2022 and held it in 1 quarter. The position peaked at $5.65K in Q4 2022. 553 funds tracked by Wall St. Rank hold BMRN as of Q1 2023.

  • New England Capital Financial Advisors reported no remaining BioMarin Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • New England Capital Financial Advisors sold 51 BioMarin Pharmaceuticals shares in Q1 2023, an estimated $5.65K.
  • New England Capital Financial Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • New England Capital Financial Advisors's BioMarin Pharmaceuticals position peaked at $5.65K in Q4 2022.
  • 553 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2023.

Based on New England Capital Financial Advisors's 13F filing for Q1 2023, filed 4 May 2023.